Phase 1 Kidney Cancer Trial, Recruiting NCT04969354 Sponsor: The Affiliated Hospital of Xuzhou Medical University Condition: Kidney Cancer
Back to Kidney Cancer

Phase 1 Kidney Cancer Trial, Recruiting

NCT04969354
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 70 years old (male or female)
  • People whose general physical functioning is rated at a certain level by their doctor (an ECOG score of 2 or lower, meaning they are able to care for themselves but may not be able to do heavy physical work — confirm with trial site)
  • People who have advanced or spreading kidney cancer, and who have previously received two lines of targeted therapy, have received no more than two rounds of immunotherapy (using PD-1/L1 treatments), or are unable to tolerate targeted therapy or immunotherapy
  • People who have at least one area of cancer that can be measured or tracked on scans
  • People whose liver, kidney, lung, and heart are functioning at an acceptable level based on blood and other tests
  • People (or their legal guardians) who are willing to take part and have signed a consent form

Who may not be able to join:

  • People who have certain infectious diseases, such as HIV, active hepatitis B or C, or active tuberculosis
  • People whose immune cells do not respond well enough in a laboratory test done during the screening process (confirm with trial site)
  • People whose vital signs are unstable or who are unable to cooperate with medical examinations
  • People who have a mental health condition that would prevent them from cooperating with treatment or assessments
  • People who have a history of severe allergic reactions, particularly to a substance called IL-2
  • People who currently have a serious infection that requires treatment
  • People who have significant problems with the functioning of major organs such as the heart, lungs, brain, liver, or kidneys
  • People who have another type of cancer in addition to kidney cancer
  • People whose doctor identifies another reason that makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Junnian Zheng, M.D/Ph.D, The Affiliated Hospital of Xuzhou Medical University

Phone: 0086-17798835021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Registry
ClinicalTrials.gov
Start date
1 October 2021
Est. completion
30 September 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety evaluation:Incidence and severity of adverse events; Effectiveness evaluation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov